Silexion completes initial study of SIL-204 in pancreatic cancer models
Silexion Therapeutics (SLXN) announced the completion of its initial study evaluating SIL-204 in orthotopic pancreatic cancer models. This ...
Silexion Therapeutics Announces Completion of Initial Study in Orthotopic Pancreatic Cancer Models Evaluating Systemic Administration of SIL-204
The Company anticipates sharing initial results from the study in March 2025. These results will inform Silexion's development strategy for SIL-204.